Profound Medical CORP

New data from the CAPTAIN trial indicates Profound Medical's TULSA Procedure preserves penile length better than robotic radical prostatectomy at one month post-treatment.

Profound Medical Corp. announced plans to release its second quarter 2026 financial results on August 6, 2026, followed by a conference call.

Profound Medical Corp. announced its TULSA Procedure will be featured in multiple presentations at the Society of Robotic Surgery Annual Meeting.

Profound Medical Corp. shareholders elected eight directors and approved the company's long-term incentive plan.

Profound Medical Corp. announced its TULSA Procedure will be featured in four oral presentations at the American Urological Association's Annual Meeting, alongside an initiative to explore PSMA PET integration for enhanced planning and monitoring.

Profound Medical Corp. will release its first quarter 2026 financial results after market close on May 7, 2026.

Profound Medical Corp. reported significant revenue growth in Q3 2025, but faces a material uncertainty regarding its ability to continue as a going concern due to declining cash and projected debt covenant breach.

Profound Medical Corp. reported a significantly wider net loss for Q2 2025, driven by substantial increases in operating expenses, despite revenue growth for the six-month period.

Profound Medical Corp. saw an 82% increase in revenue in Q1 2025, driven by higher recurring revenue in the United States and capital sales overseas.

Profound Medical Corp. reported a 51% increase in revenue for the year ended December 31, 2025, driven by strong TULSA-PRO sales, but also saw its net loss widen to $42.57 million.

Profound Medical's 2024 10-K filing reveals a focus on commercializing TULSA-PRO and Sonalleve systems, expanding market reach, and navigating regulatory landscapes.

CEO Arun Swarup Menawat reports purchasing additional Profound Medical Corp. shares in two transactions.

Gagnon Securities LLC, Gagnon Advisors, LLC, and Neil Gagnon report their beneficial ownership of Profound Medical Corp. common shares as of December 31, 2024.